For patients with advanced melanoma receiving anti-PD-1 treatment (n = 49) in Riaz et al. cohort, overall survival were compared between patients with low PTEN expression (the bottom fifth, n = 10) and high PTEN expression (the top four fifths, n = 39). Here, PDCD1 is linked to melanoma.